A First-in-Human Study of EOS301984 as Monotherapy or Combination Therapy in Adult Participants With Advanced Solid Tumors
Phase 1
Recruiting
- Conditions
- Advanced Solid Tumors
- Interventions
- Drug: EOS301984Drug: Anti-PD-1 monoclonal antibody
- First Posted Date
- 2024-08-09
- Last Posted Date
- 2024-08-09
- Lead Sponsor
- iTeos Therapeutics
- Target Recruit Count
- 84
- Registration Number
- NCT06547957
- Locations
- 🇧🇪
Institut Jules Bordet, Brussels, Belgium
🇧🇪CHU de Liège, Liège, Belgium
🇧🇪Universitair Ziekenhuis Gent, Ghent, Belgium
New Formulation Study of Inupadenant (EOS100850) in Patients With Cancer
Phase 1
Recruiting
- Conditions
- Solid Tumor, Adult
- Interventions
- Drug: Inupadenant
- First Posted Date
- 2021-11-11
- Last Posted Date
- 2023-05-03
- Lead Sponsor
- iTeos Therapeutics
- Target Recruit Count
- 64
- Registration Number
- NCT05117177
- Locations
- 🇧🇪
GZA Ziekenhuizen, Wilrijk, Antwerpen, Belgium
🇧🇪Institut Jules Bordet, Anderlecht, Belgium
🇧🇪Cliniques Universitaires St-Luc, Brussels, Belgium
First-in-Human Study of EOS100850 in Patients With Cancer
Phase 1
Active, not recruiting
- Conditions
- Solid Tumor, Adult
- Interventions
- First Posted Date
- 2019-03-14
- Last Posted Date
- 2023-12-27
- Lead Sponsor
- iTeos Therapeutics
- Target Recruit Count
- 119
- Registration Number
- NCT03873883
- Locations
- 🇫🇷
Centre de Lutte Contre le Cancer - Institut de Cancerologie de l'Ouest - Rene Gauducheau, Saint-Herblain, France
🇺🇸Karmanos Cancer Institute, Michigan Center, Michigan, United States
🇺🇸John Theurer Cancer Center, Hackensack University Medical Center, Hackensack, New Jersey, United States
© Copyright 2025. All Rights Reserved by MedPath